Roche and BMS leverage AI for the treatment of solid tumors – PharmaLive
rock at in partnership with Bristol Myers Squibb use two digital pathology platforms that would advance research into treatment options for patients diagnosed with solid tumors.
Both projects harness the capabilities of artificial intelligence and computer technology in digital pathology to help healthcare professionals achieve more accurate and comprehensive results and improve treatment outcomes.
The first project involves Roche Digital Pathology creating an AI-based image analysis algorithm that will help pathologists evaluate the ventana PD-L1 test in the market, which Bristol Myers Squibb will use to generate data biomarkers from clinical trial samples.
The second project includes Roche’s Open Environment partnership with PathAI to integrate a CD8 biomarker assessment algorithm into Navify Digital Pathology software. Bristol Myers Squibb will use this second platform to assess clinical trial samples that have been stained with the CD8 assay and generate biomarker data.
“We believe that digital methods will bring significant improvements in the standardization and interpretation of tissue-based tests and enable wider access to tissue-based tests. The ability to more deeply interrogate images will provide opportunities to better understand disease biology, which could lead to expanded and improved drug development options and ultimately highly effective patient selection strategies,” said Sarah Hersey, Vice President of Bristol’s Translational Sciences and Diagnostics Branch. Myers Squibb, in a statement.
The goal of both projects is to generate information that can be used to advance personalized treatment options and aid in more accurate cancer diagnoses. Roche’s pathology laboratory solutions have the ability to perform end-to-end processes, from tissue staining to high-quality digital imaging. These are combined with modern AI-based image analysis tools and deep learning methods to help healthcare providers gain meaningful insights based on tissue samples. The integration of AI also means faster diagnostics and reduced risk of human error.
“The Bristol Myers Squibb and PathAI collaborations are among the first examples where AI technology and digital pathology applications are playing a role in developing treatments for patients. By using our NAVIFY Digital platform to interpret tissue-based testing and AI algorithms, pathologists are better able to identify targeted treatment options, improving patient care,” noted Jill German, Head of Roche Diagnostics Pathology Customer Area, in the same press release.
the Roche digital pathology open environment was launched in September 2021 to enable the secure exchange and flow of data, allowing pathologists to access advanced technology from third-party vendors alongside the company’s own AI-based image analysis tools business. This enables software developers to distribute their digital products globally through Roche, with the aim of making the work of pathologists around the world easier and faster.
Roche has two deployment options for its technology: the Ventana DP 200 slide scanner and uPath enterprise software, both CE-IVD marked for use in in vitro diagnostics. They are available in the United States for research purposes.
Financial terms of the collaboration, if any, were not disclosed.